SMTI — Sanara MedTech Inc.

Summary of Sanara MedTech (SMTI) Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Full Year 2025 Revenue: $103.1 million, a 19% increase year-over-year, marking the first time the company exceeded $100 million in net revenue.
• Q4 2025 Revenue: $27.5 million, a 5% increase year-over-year; excluding a $1.8 million impact from Hurricane Helene in Q4 2024, growth was 13%.
• Gross Margin: Expanded to 93%, up approximately 200 basis points year-over-year.
• Net Loss: Reduced to $1.1 million in Q4 2025 from a profit of $0.9 million in Q4 2024.
• Adjusted EBITDA: Increased to $4.7 million in Q4 2025 from $4.1 million in the prior year.
• Cash Flow from Operations: Generated $6.8 million for the full year 2025, a significant improvement from $24,000 used in 2024.

2. Strategic Updates and Business Highlights:

• Commercial Strategy: Focused on three initiatives: strengthening distributor relationships, expanding into new healthcare facilities, and increasing surgeon adoption within existing facilities.
• Distributor Network: Grew from over 350 to over 450 contracted distributors in 2025.
• Facility Expansion: Successfully sold into over 1,450 healthcare facilities by year-end 2025, up from over 1,300 in 2024.
• Product Development: Secured an Innovative Technology contract with Vizient for BIASURGE, expanding access to 1,800 healthcare facilities.
• Clinical Evidence: Published studies supporting BIASURGE and ALLOCYTE Plus, enhancing product credibility and market positioning.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to 2025.
• Q1 2026 Revenue Expectation: Anticipated net revenue of approximately $26.7 million to $27.2 million, reflecting growth of 14% to 16% year-over-year.
• Strategic Focus for 2026: Continued penetration of the surgical wound market, targeted investments in sales and R&D, and preparation for the U.S. launch of OsStic in Q1 2027.

4. Bad News, Challenges, or Points of Concern:

• Net Loss in Q4: Transitioned from a profit in Q4 2024 to a loss in Q4 2025, raising concerns about profitability despite revenue growth.
• Operating Expenses: Increased by 13% in Q4, driven by a noncash impairment charge of $1.8 million related to IP assets, which could indicate challenges in asset management.
• Competitive Pressures: The need to continually demonstrate clinical and economic value to maintain and grow market share in a competitive landscape.

5. Notable Q&A Insights:

• BIASURGE Growth Attribution: The Vizient contract is expected to significantly contribute to growth in 2026, although education at the facility level will take time.
• CellerateRX Reimbursement: The product is not subject to reimbursement risk, which is seen as a competitive advantage; ongoing clinical and economic studies are expected to bolster its market position.
• Focus on Clinical Evidence: Strong emphasis on the importance of clinical data to support product adoption and relationships with healthcare facilities.

Overall, Sanara MedTech demonstrated solid growth in 2025, with strategic initiatives aimed at expanding its market presence and enhancing product offerings. However, the transition to a net loss in Q4 and rising operating expenses highlight areas for careful management moving forward.